ProCE Banner Activity

My Perspective on the Status of Neoadjuvant Therapy in Melanoma

Clinical Thought
Gain insights into the rationale and evidence for neoadjuvant therapy in melanoma in this expert commentary.

Released: July 15, 2021

Expiration: July 14, 2022

No longer available for credit.

Share

Faculty

Jeffrey S. Weber

Jeffrey S. Weber, MD, PhD

Senior Member and Director
Comprehensive Melanoma Research Center
H. Lee Moffitt Cancer Center
Tampa, Florida

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Merck Sharp & Dohme Corp.

Program Director Disclosure

Program Director

Jeffrey S. Weber, MD, PhD

Senior Member and Director
Comprehensive Melanoma Research Center
H. Lee Moffitt Cancer Center
Tampa, Florida

Jeffrey S. Weber, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Moderna, Novartis, and Pfizer.